EUVIMEDEUVIMED entdecken
Open Access

Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020

Mufaddal Mahesri, Ameet Sarpatwari, Krista F Huybrechts, Joyce Lii, Su Been Lee, Gita A Toyserkani, Cynthia LaCivita, Esther H Zhou, Gerald J Dal Pan, Aaron S Kesselheim, Katsiaryna Bykov

Drug Safety · 2024

DOI: 10.1007/s40264-024-01443-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Safety, 2024. Verfasst von Mufaddal Mahesri und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont…. Hauptthemen laut MEDLINE: Thalidomide, Lenalidomide. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIA NIH HHS, Center for Drug Evaluation and Research, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ThalidomideLenalidomideHumansFemaleUnited StatesPregnancyMiddle AgedAdultRisk Evaluation and MitigationMultiple MyelomaUnited States Food and Drug AdministrationAgedDatabases, Factual

Substanzen

ThalidomideLenalidomidepomalidomide

Autor:innen und Institutionen

  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street (Suite 3030), Boston, MA, 02120, USA. mmahesri@mgh.harvard.edu.
  • Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, 1620 Tremont Street (Suite 3030), Boston, MA, 02120, USA.
  • Program on Regulation, Therapeutics, and Law, Boston, MA, USA.
  • Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA.

Förderung

  • NIA NIH HHS
  • Center for Drug Evaluation and Research
  • NIH HHS
  • National Institutes of Health
  • Arnold Ventures

Zitieren

APA

Mahesri, M., Sarpatwari, A., Huybrechts, K. F., Lii, J., Lee, S. B., Toyserkani, G. A., LaCivita, C., Zhou, E. H., Dal Pan, G. J., Kesselheim, A. S., & Bykov, K. (2024). Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020. Drug Safety. https://doi.org/10.1007/s40264-024-01443-3

Vancouver

Mahesri M, Sarpatwari A, Huybrechts KF, Lii J, Lee SB, Toyserkani GA, et al. Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020. Drug Safety. 2024. doi:10.1007/s40264-024-01443-3

BibTeX
@article{Mahesri2024,
  author = {Mahesri, Mufaddal and Sarpatwari, Ameet and Huybrechts, Krista F and Lii, Joyce and Lee, Su Been and Toyserkani, Gita A and LaCivita, Cynthia and Zhou, Esther H and Dal Pan, Gerald J and Kesselheim, Aaron S and Bykov, Katsiaryna},
  title = {Trends in Use and Evidence of Adherence to Risk Evaluation and Mitigation Strategy Pregnancy Testing Requirements for Thalidomide, Lenalidomide, and Pomalidomide in the USA, 2000–2020},
  journal = {Drug Safety},
  year = {2024},
  doi = {10.1007/s40264-024-01443-3}
}
Kostenlos starten →